Literature DB >> 16778199

Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression.

Frédérique Souazé1, Sandra Dupouy, Véronique Viardot-Foucault, Erik Bruyneel, Samir Attoub, Christian Gespach, Anne Gompel, Patricia Forgez.   

Abstract

Emerging evidence supports neurotensin as a trophic and antiapoptotic factor, mediating its control via the high-affinity neurotensin receptor (NT1 receptor) in several human solid tumors. In a series of 51 patients with invasive ductal breast cancers, 34% of all tumors were positive for neurotensin and 91% positive for NT1 receptor. We found a coexpression of neurotensin and NT1 receptor in a large proportion (30%) of ductal breast tumors, suggesting a contribution of the neurotensinergic signaling cascade within breast cancer progression. Functionally expressed NT1 receptor, in the highly malignant MDA-MB-231 human breast cancer cell line, coordinated a series of transforming functions, including cellular migration, invasion, induction of the matrix metalloproteinase (MMP)-9 transcripts, and MMP-9 gelatinase activity. Disruption of NT1 receptor signaling by silencing RNA or use of a specific NT1 receptor antagonist, SR48692, caused the reversion of these transforming functions and tumor growth of MDA-MB-231 cells xenografted in nude mice. Our findings support the contribution of neurotensin in human breast cancer progression and point out the utility to develop therapeutic molecules targeting neurotensin or NT1 receptor signaling cascade. These strategies would increase the range of therapeutic approaches and be beneficial for specific patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778199     DOI: 10.1158/0008-5472.CAN-06-0450

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Activation of matrix metalloproteinase-9 (MMP-9) by neurotensin promotes cell invasion and migration through ERK pathway in gastric cancer.

Authors:  Hafeza Akter; Min Park; Oh-Seung Kwon; Eun Joo Song; Won-Sang Park; Min-Jung Kang
Journal:  Tumour Biol       Date:  2015-02-28

2.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

Review 3.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

4.  Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.

Authors:  Germana Rappa; Fabio Anzanello; Aurelio Lorico
Journal:  Cancer Chemother Pharmacol       Date:  2010-07-02       Impact factor: 3.333

5.  The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.

Authors:  Kohei Hashimoto; Yuki Kyoda; Toshiaki Tanaka; Toshihiro Maeda; Ko Kobayashi; Kohsuke Uchida; Hiroshi Kitamura; Koichi Hirata; Taiji Tsukamoto; Naoya Masumori
Journal:  Lab Invest       Date:  2015-01-12       Impact factor: 5.662

6.  Hydrophilic 18F-labeled trans-5-oxocene (oxoTCO) for efficient construction of PET agents with improved tumor-to-background ratios in neurotensin receptor (NTR) imaging.

Authors:  Mengzhe Wang; Raghu Vannam; William D Lambert; Yixin Xie; Hui Wang; Benjamin Giglio; Xiaofen Ma; Zhanhong Wu; Joseph Fox; Zibo Li
Journal:  Chem Commun (Camb)       Date:  2019-02-21       Impact factor: 6.222

7.  Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.

Authors:  Yanli Zhang; Shunqin Zhu; Liang Yi; Yaling Liu; Hongjuan Cui
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

8.  Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.

Authors:  Mikaël Agopiantz; Patricia Forgez; Jean-Matthieu Casse; Stéphanie Lacomme; Claire Charra-Brunaud; Isabelle Clerc-Urmès; Olivier Morel; Céline Bonnet; Jean-Louis Guéant; Jean-Michel Vignaud; Anne Gompel; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-08-24       Impact factor: 4.064

9.  A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.

Authors:  Elisa García-Garayoa; Peter Bläuenstein; Alain Blanc; Veronique Maes; Dirk Tourwé; P August Schubiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

10.  Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.

Authors:  Yinnong Jia; Wen Shi; Zhengyuan Zhou; Nilesh K Wagh; Wei Fan; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2015-07-29       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.